Sanofi Completes Dosing in Phase 1 Trial of 'Dupixent' Utilizing Alteogen's Technology
Sanofi's 'Dupixent' (ingredient: dupilumab), which utilizes Alteogen's subcutaneous (SC) injection platform technology, has completed dosing for participants in its phase 1 clinical trial.
Exterior view of Alteogen headquarters and research center in Yuseong-gu, Daejeon. Alteogen
View original imageAccording to the clinical information site ClinicalTrials on July 23, Sanofi plans to complete its phase 1 clinical trial of Dupixent, administered in combination with Alteogen's hyaluronidase 'ALT-B4' (ingredient: verahyaluronidase alpha), by September.
This phase 1 trial, which began in June, was conducted on 40 healthy adult participants. The purpose of the trial is to evaluate the pharmacokinetics (PK), safety, and anti-drug antibodies (ADA) following the co-administration of Dupixent and ALT-B4.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The ALT-B4 used in this trial is a recombinant human hyaluronidase enzyme developed by Alteogen, enabling the subcutaneous injection of large-volume drugs and facilitating their absorption in the body. Sanofi is utilizing Alteogen's technology to develop a new formulation of Dupixent aimed at improving dosing convenience.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.